English, Article edition: Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy: Implications for Decision Making Cornelis Boersma; Jarir Atthobari; Ron T. Gansevoort; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/118579
Physical Description
  • article
Language
  • English

Edition details

Title
  • Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy: Implications for Decision Making
Author
  • Cornelis Boersma
  • Jarir Atthobari
  • Ron T. Gansevoort
  • Lolkje T.W. de Jong-Van den Berg
  • Paul E. de Jong
  • Dick de Zeeuw
  • Lieven J.P. Annemans
  • Maarten J. Postma
Physical Description
  • article
Notes
  • Angiotensin II receptor antagonists (angiotensin II receptor blockers; ARBs) are a class of antihypertensive drugs that are generally considered comparable to ACE inhibitors in the prevention of heart and kidney failure. However, these two classes of agents do interfere in different stages of the renin-angiotensin system. In patients with type 2 diabetes mellitus, advantages for ARBs over conventional (non-ACE inhibitor) therapy on progression from micro- to macroalbuminuria and overt nephropathy and end-stage renal disease have been shown in clinical trials. In patients with type 2 diabetes and end-stage renal disease, the need for dialysis and/​or transplantation results in the use of major healthcare resources. This paper reviews the available economic evidence on treatment with ARBs in type 2 diabetic patients with advanced renal disease. Within-trial analytic and Markov model economic evaluations of the RENAAL (Reduction of Endpoint in Non-insulin dependent diabetes mellitus with Angiotensin II Antagonist Losartan), IDNT (Irbesartan Diabetic Nephropathy Trial) and IRMA (IRbesartan in type 2 diabetes with MicroAlbuminuria)-2 studies suggest that treatment with ARBs in patients with type 2 diabetes with overt or incipient nephropathy confers health gains and net cost savings compared with conventional (non-ACE inhibitor) therapy. For reimbursement and reference pricing decisions, there is a need for a head-to-head comparison of an ACE inhibitor with ARBs to model all possible costs and effects of ACE inhibitors and ARBs. This will result in a proper pharmacoeconomic outcome, where both types of drugs can be compared for healthcare decisions.
  • ACE-inhibitors, Angiotensin-II-receptor-antagonists, Diabetic-nephropathies, Economic-implications
  • RePEc:wkh:phecon:v:24:y:2006:i:6:p:523-535
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment